Examples such as aducanumab have been prominent in recent years; however, the commercialization of the former was rejected by several drug agencies, while Lecanemab showed highly significant results in phase 3 but attracted controversial opinions on its previous performance [ 9 , 10 , 11 ].
← all excerpts
Polyoxometalate-Decorated Gold Nanoparticles Inhibit β-Amyloid Aggregation and Cross the Blood-Brain Barrier in a µphysiological Model.
1
—
—